编辑HBG1和HBG2基因诱导胎儿血红蛋白
该临床前研究通过CRISPR/Cas9破坏HBG1/HBG2启动子中BCL11A结合基序,在正常及镰状细胞病供者CD34+细胞中实现高频率靶向突变并诱导HbF至潜在治疗水平。异种移植后16-17周未见CD34+细胞再生或分化受损,CIRCLE-seq候选位点靶向测序未检出脱靶突变。含3个核定位信号的Cas9编辑效率优于常规2个核定位信号的Cas9。
要点
- 破坏HBG1/HBG2启动子BCL11A结合基序可诱导HbF至潜在治疗水平
- 靶向编辑未损害CD34+细胞再生及红系、T、B、髓系分化
- 3个核定位信号的Cas9编辑效率优于常规2个核定位信号的Cas9
核心结论
- 破坏HBG1/HBG2启动子BCL11A结合基序可安全、可行、有效地诱导HbF,为血红蛋白病治疗提供临床前证据。
研究设计与样本
- 临床前研究:将Cas9单导向RNA核糖核蛋白复合物电穿孔导入正常及镰状细胞病供者CD34+造血干/祖细胞,并移植至NOD/SCID/Il2rγ-/-/KitW41/W41免疫缺陷小鼠。
主要发现
- 电穿孔后获得高频率的靶向突变,并在体外及异种移植后体内产生的红系后代中诱导HbF至潜在治疗水平。
- 异种移植后16至17周,靶向编辑未损害CD34+细胞再生或向红系、T、B、髓系细胞谱系的分化。
- 经CIRCLE-seq识别的候选位点靶向测序未检测到脱靶突变。
- 含3个核定位信号的工程化Cas9比含2个核定位信号的常规Cas9编辑人造血干/祖细胞更高效、更稳定。
临床怎么用
- 该机制性诱导HbF的策略在临床前模型中显示安全、可行且有效,支持进一步临床转化评估。
局限性
- 最佳技术方案及限制性毒性尚未完全明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Induction of fetal hemoglobin (HbF) via clustered regularly interspaced short palindromic repeats/Cas9-mediated disruption of DNA regulatory elements that repress γ-globin gene (HBG1 and HBG2) expression is a promising therapeutic strategy for sickle cell disease (SCD) and β-thalassemia, although the optimal technical approaches and limiting toxicities are not yet fully defined. We disrupted an HBG1/HBG2 gene promoter motif that is bound by the transcriptional repressor BCL11A. Electroporation of Cas9 single guide RNA ribonucleoprotein complex into normal and SCD donor CD34+ hematopoietic stem and progenitor cells resulted in high frequencies of on-target mutations and the induction of HbF to potentially therapeutic levels in erythroid progeny generated in vitro and in vivo after transplantation of hematopoietic stem and progenitor cells into nonobese diabetic/severe combined immunodeficiency/Il2rγ-/-/KitW41/W41 immunodeficient mice. On-target editing did not impair CD34+ cell regeneration or differentiation into erythroid, T, B, or myeloid cell lineages at 16 to 17 weeks after xenotransplantation. No off-target mutations were detected by targeted sequencing of candidate sites identified by circularization for in vitro reporting of cleavage effects by sequencing (CIRCLE-seq), an in vitro genome-scale method for detecting Cas9 activity. Engineered Cas9 containing 3 nuclear localization sequences edited human hematopoietic stem and progenitor cells more efficiently and consistently than conventional Cas9 with 2 nuclear localization sequences. Our studies provide novel and essential preclinical evidence supporting the safety, feasibility, and efficacy of a mechanism-based approach to induce HbF for treating hemoglobinopathies.
引用
- Métais JY, Doerfler PA, Mayuranathan T, et al. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Adv. 2019. PMID: 31698466. doi:10.1182/bloodadvances.2019000820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。